Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
atevirdine mesylate + zidovudine
- Development stage
- Discontinued
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Atevirdine mesylate + zidovudine is a combination of two antiretroviral agents intended for the treatment of HIV infection. **Atevirdine mesylate** (not approved/marketed, closely related to delavirdine) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that inhibits HIV-1 reverse transcriptase by binding allosterically, disrupting viral replication. **Zidovudine** is a nucleoside reverse transcriptase inhibitor (NRTI) that functions as a thymidine analog, incorporates into viral DNA, and leads to chain termination, also inhibiting HIV-1 reverse transcriptase. The combination targets HIV replication at two mechanistic points in the viral life cycle and was studied for additive or synergistic effects. No evidence of a marketed atevirdine mesylate + zidovudine product was found; atevirdine mesylate itself was only studied experimentally.
- Brand names
- none known for the combinationRESCRIPTOR (delavirdine mesylate)RetrovirCombivirTrizivirnothing found for atevirdine mesylate as approved
- Other names
- none known for the combination formulaatevirdine mesylate (experimental)AZTZDVazidothymidine (for zidovudine)
02
Targets
Human immunodeficiency virus type 1 reverse transcriptase
Beyond the preview
Go deeper on atevirdine mesylate + zidovudine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on atevirdine mesylate + zidovudine.